Apollon Formularies plc Total Voting Rights (5970U)
02 Agosto 2022 - 10:11AM
UK Regulatory
TIDMAPOL
RNS Number : 5970U
Apollon Formularies plc
02 August 2022
2 August 2022
Apollon Formularies Plc
("Apollon" or the "Company")
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure
and Transparency Rules, the Company hereby announces that it has
771,191,266 ordinary shares of no par value each in issue, each
share carrying the right to one vote.
This figure of 771,191,266 ordinary shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the FCA's Disclosure and Transparency Rules.
The directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information please contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis and
medicinal mushroom pharmaceutical company headquartered in the
United Kingdom. Apollon Formularies Jamaica Limited is a
pharmaceutical company incorporated and operating in the
Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by
the Jamaican government's Cannabis Licensing Authority (CLA) to
cultivate (R&D), perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis to treat various illnesses under medical
supervision.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXPTMPTMTMMMLT
(END) Dow Jones Newswires
August 02, 2022 04:11 ET (08:11 GMT)
Grafico Azioni Apollon Formularies (AQSE:APOL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Apollon Formularies (AQSE:APOL)
Storico
Da Giu 2023 a Giu 2024